WB
Vir
Transfected Only
200, 120
Mouse IgG1 kappa
#K9N5Q8
37616432
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Virus
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val534 of MERS-CoV spike protein.
Background
Middle East Respiratory Syndrome (MERS) is a contagious viral respiratory infection, whose causative agent was identified as the MERS-related coronavirus (MERS-CoV) (1,2). MERS-CoV is a single-stranded mRNA betacoronavirus; similar to other infectious coronaviruses (e.g., SARS-CoV-2), the MERS-CoV virion is comprised of four key structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3). Coronavirus spike proteins are class I fusion proteins that harbor an ectodomain, a transmembrane domain, and an intracellular tail. The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases (4). MERS-CoV spike proteins utilize the cell surface protein DPP4/CD26 as the receptor for cellular entry (5,6); notably, this protein displays no structural similarities to ACE2, the primary receptor for SARS-CoV-1 and SARS-CoV-2. Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (7,8).
- Bermingham, A. et al. (2012) Euro Surveill 17, 20290.
- de Groot, R.J. et al. (2013) J Virol 87, 7790-2.
- van Boheemen, S. et al. (2012) mBio 3, e00473-12. doi: 10.1128/mBio.00473-12.
- Jiang, S. et al. (2013) J Infect 66, 464-6.
- Wang, N. et al. (2013) Cell Res 23, 986-93.
- Raj, V.S. et al. (2013) Nature 495, 251-4.
- Du, L. et al. (2009) Nat Rev Microbiol 7, 226-36.
- Yuan, Y. et al. (2017) Nat Commun 8, 15092.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.